IHC was performed on ovarian cancer tissue, used as a positive control [47] to validate TFRC antibody immunoreactivity (-ir), and on five primary GIST tissues with different clinicopathological features (Table S1). The gene discussed is TFRC; the disease is ovarian carcinoma.